FLAG-IDA May Induce Second Chronic Phase in Patients With Chronic Myeloid Leukemia
Researchers sought to determine whether treatment with FLAG-IDA could induce a second chronic phase in patients with CML.
Chronic Myeloid Leukemia
Asciminib Shows Superior Efficacy to Bosutinib for Patients With CML in Chronic Phase
Researchers sought to determine whether asciminib would be better than bosutinib for treating patients with chronic myeloid leukemia in chronic phase.
Chronic Myeloid Leukemia: 5 Myths You May Encounter
Patients may not have much information on chronic myeloid leukemia, and some may have a number of misunderstandings surrounding the condition. As a health care professional, what are some of these myths you can correct to better educate patients?
Algorithm Assesses Risk of Major Adverse Cardiovascular Events in TKI-Treated CML
Researchers sought to determine the accuracy of established cardiovascular assessment tools in predicting risk of CV events in patients with CML receiving TKIs.
Comparison of Generic and Branded Imatinib for Patients With Chronic Myeloid Leukemia
Researchers sought to determine whether there was a difference in generic or branded imatinib in treating patients with CML.
Optimal Starting Dose of Ponatinib for Chronic Phase Chronic Myeloid Leukemia
Researchers evaluated the benefit-risk ratio across 3 ponatinib starting doses in patients with chronic phase chronic myeloid leukemia.
Review of the Cardiovascular Risks of TKI Therapy for Chronic Myeloid Leukemia
Tyrosine kinase inhibitors have improved survival outcomes for patients with CML, but these agents also have a greater risk for adverse cardiovascular events.
Tipifarnib May Yield Response in Chronic Myelomonocytic Leukemia or Other Myelodysplastic, Myeloproliferative Neoplasms
Among patients with CML, 32 were evaluable for ORR, which was determined to be 21.9%.
Dose-Optimization of Ponatinib in Patients With Resistant/Intolerant Chronic-Phase Chronic Myeloid Leukemia
Researchers sought to determine the optimal benefit/risk profile for ponatinib in patients with resistant/intolerant chronic-phase chronic myeloid leukemia.
Age and Race May Determine Whether Cancer Patients Access Their Electronic Health Records
Black cancer patients were 44% less likely than White patients to enroll in a portal that provides access to electronic health records.
- Loading...
Loading...
Next post in General Medicine
Loading... 
Loading...